Ruibo Biotech announced that in accordance with the share repurchase authorization, the company purchased a total of 186,600 H shares in the open market on July 13, 2026, at a total cost of HK$9.3012 million. All such repurchased H shares are held as treasury shares.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.